NCT04190056: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

NCT04190056
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic antibody, Endocrine (Hormone) therapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have greater than 10% expression of PD-1/CTLA-4 in tumor or blood
Exclusions: Patients with prior treatment of pembrolizumab (Keytruda) or other PD-(L)1 inhibitor; Patients with uncontrolled unstable symptomatic brain metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT04190056

Comments are closed.

Up ↑